264 related articles for article (PubMed ID: 32344314)
1. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Apr; 140():109777. PubMed ID: 32344314
[TBL] [Abstract][Full Text] [Related]
2. Expression of NKG2A inhibitory receptor on cytotoxic lymphocytes as an indicator of severity in Corona Virus Disease 2019 (COVID-19) patients.
Yasin MM; Shehata IH; Elsheikh NG; Elsayed MS
Egypt J Immunol; 2021 Jul; 28(3):157-167. PubMed ID: 34453787
[TBL] [Abstract][Full Text] [Related]
3. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
[TBL] [Abstract][Full Text] [Related]
4. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
McWilliams EM; Mele JM; Cheney C; Timmerman EA; Fiazuddin F; Strattan EJ; Mo X; Byrd JC; Muthusamy N; Awan FT
Oncoimmunology; 2016; 5(10):e1226720. PubMed ID: 27853650
[TBL] [Abstract][Full Text] [Related]
6. HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease.
Hosseini E; Minagar A; Ghasemzadeh M; Arabkhazaeli A; Ghasemzadeh A
Hum Immunol; 2023 Apr; 84(4):263-271. PubMed ID: 36822912
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of CD94/NKG2A inhibitory receptors on CD8+ T cells in HIV infection is more pronounced in subjects with detected viral load than in their aviraemic counterparts.
Zeddou M; Rahmouni S; Vandamme A; Jacobs N; Frippiat F; Leonard P; Schaaf-Lafontaine N; Vaira D; Boniver J; Moutschen M
Retrovirology; 2007 Oct; 4():72. PubMed ID: 17927817
[TBL] [Abstract][Full Text] [Related]
8. NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade.
Lee G; Schauner R; Burke J; Borocz J; Vasana S; Sobieraj L; Giraudo M; Jackson Z; Ansari Q; Navas M; Sakr H; Wald D
Front Immunol; 2023; 14():1022890. PubMed ID: 37483595
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
Hammer Q; Dunst J; Christ W; Picarazzi F; Wendorff M; Momayyezi P; Huhn O; Netskar HK; Maleki KT; García M; Sekine T; Sohlberg E; Azzimato V; Aouadi M; ; ; Degenhardt F; Franke A; Spallotta F; Mori M; Michaëlsson J; Björkström NK; Rückert T; Romagnani C; Horowitz A; Klingström J; Ljunggren HG; Malmberg KJ
Cell Rep; 2022 Mar; 38(10):110503. PubMed ID: 35235832
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers.
Saito M; Braud VM; Goon P; Hanon E; Taylor GP; Saito A; Eiraku N; Tanaka Y; Usuku K; Weber JN; Osame M; Bangham CR
Blood; 2003 Jul; 102(2):577-84. PubMed ID: 12560226
[TBL] [Abstract][Full Text] [Related]
13. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
14. Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T; André P; Horowitz A; Ruan DF; Borst L; Zerbib R; Narni-Mancinelli E; van der Burg SH; Vivier E
J Immunother Cancer; 2019 Oct; 7(1):263. PubMed ID: 31623687
[TBL] [Abstract][Full Text] [Related]
15. Altered CD94/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions.
Pace E; Di Sano C; Ferraro M; Tipa A; Olivieri D; Spatafora M; Santagata R; Bellia V; Gjomarkaj M
Eur J Cancer; 2011 Jan; 47(2):296-304. PubMed ID: 20932742
[TBL] [Abstract][Full Text] [Related]
16. The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.
Rapaport AS; Schriewer J; Gilfillan S; Hembrador E; Crump R; Plougastel BF; Wang Y; Le Friec G; Gao J; Cella M; Pircher H; Yokoyama WM; Buller RM; Colonna M
Immunity; 2015 Dec; 43(6):1112-24. PubMed ID: 26680205
[TBL] [Abstract][Full Text] [Related]
17. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
18. Association of NKG2A with treatment for chronic hepatitis C virus infection.
Harrison RJ; Ettorre A; Little AM; Khakoo SI
Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
20. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
